Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Investor Presentation (November 2025)
39 slides from Zydus Lifesciences's investor presentation, Nov 25, 2025
Slide 1: Exchange cover letter: submission of corporate presentation
November 25, 2025 BSE Limited National Stock Exchange of India Limited Corporate Relations Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1, G Block Dalal Street Bandra Kurla Complex Fort, Mumbai 400 001 Bandra (East), Mumbai 400 051 Maharashtra, India Maharashtra
Slide 2: Zydus Lifesciences Limited Corporate Presentation November 2025
Zydus Lifesciences Limited Corporate Presentation November 2025
Slide 3: Disclaimer
Disclaimer This presentation is issued by Zydus Lifesciences Limited (the “Company”) for general information purposes only, without regard to specific objectives, suitability, financial situations and needs of any particular person. This presentation does not constitute or form part of any offer or
Slide 4: Vision, Mission, Purpose
VISION To be a global life-sciences company transforming lives through innovative discoveries MISSION To unlock new possibilities in life-sciences through healthcare solutions that impact lives PURPOSE Empowering people with the freedom to live healthier and more fulfilled lives 3
Slide 5: Zydus Lifesciences: Innovation-led Diversified Lifesciences Company
Zydus Lifesciences: Innovation-led Diversified Lifesciences Company Global Scale and Capabilities Leadership Across Multiple Markets Portfolio and Product Pipeline Key Features of our Portfolio Leading company in India pharma; #1 in Oncology3 US$ 2.75bn US$ 835mn Fast-Growing Large Market FY25 FY25
Slide 6: Three Large Global Categories
Three Large Global Categories India US International Markets Increasing Largely #1 Company in Top 3 in ~55% Specialty Deepening Pharma Super Specialty chronic mix of products portfolio: Branded presence in (44.5%, business with TA of across multiple 505(b)(2) & IMs, leveraging +670 bps, focus on sel
Slide 7: Zydus' Portfolio Across Platforms
Zydus’ Portfolio Across Platforms Successful track-record in India on Innovation portfolio3 Portfolio3 across 505(b)(2) and Rare diseases in US on back of Organic and Inorganic Levers 4 4 15 505(b)(2)1 Advancing pipeline for global markets Launched1 Pipeline1 Spec Saroglitazar Desidustat Usnoflast i
Slide 8: Moving up the Innovation Curve
Pipeline Monetization on Track with Strengthened Commercial Capabilities – Creating an Ecosystem Focused on Patient Centricity Current Play1 Growth Drivers ▪ Scaled multiple products in India: Saroglitazar (Lipaglyn, ▪ Saroglitazar (PBC indication) – Commercialisation Bilypsa), Desidustat (Oxemia) p
Slide 9: Zydus: Strategic Partner of Choice
Zydus: Strategic Partner of Choice In-Licensing: Fill Portfolio Gaps & Supplement Our Innovation Engine Out-Licensing: Validates Our Innovation Engine ➢ Partnership with Top 10 IPM Companies1 (Saroglitazar & Collaborations Other Areas For In-Licensing Desidustat), China partnership for NCEs Desidust
Slide 10: Long Term Track Record of Value Creation
Long Term Track Record of Value Creation …Driven by Healthy Financial Performance Consistent Revenue Growth Improving Margin Profile (EBITDA) Revenue (INR Mn) 10.3% EBITDA (INR Mn) & EBITDA Margin (%) 2,32,415 CAGR 19.5% 30.4% 20.5% 70,585 Shareholder Value Creation… 1,42,531 CAGR Market Capitalizat
Slide 11: Strong Topline and Bottomline Growth Across Businesses
Strong Topline and Bottomline Growth Across Businesses Revenue (INR Mn) Business-Wise Performance3 16.1% 2,32,415 CAGR 1,95,474 10.9% Business Vertical 1,72,374 (FY23 – 25) 1,14,445 1,26,969 India Formulations 9.9% FY23 FY24 FY25 H1 FY25 H1 FY26 EBITDA (INR Mn) US Formulations 21.8% 22.4% 27.5% 30.4
Slide 12: Clearly Identified Levers of Growth
Clearly Identified Levers of Growth Our Growth Platforms Enhance Presence in Focus Therapies and Continue Scaling our Innovation led Innovation DNA and Portfolio in India Formulations Market R&D Investments Scale Up Differentiated Generics and Specialty Business in US Leverage our Global Portfolio a
Slide 13: Business Overview
zyd Dedicated To Life Business Overview
Slide 14: India Formulations: Scaled Presence with Thrust on Focus Therapy Areas
India Formulations: Scaled Presence with Thrust on Focus Therapy Areas India Formulations: Brief Overview Successfully Scaling Bigger Brands Scaled Presence: ~INR 59,300mn revenue3 (9.9% CAGR over FY23-25) # Brands - # Brands - Brand Value2 MAT Sep’21 MAT Sep’25 Leadership in super specialty and fas
Slide 15: India Formulations: Salience of Innovation Portfolio Continues to Expand
India Formulations: Salience of Innovation Portfolio Continues to Expand Strong Innovation Track-Record… Other Growth Levers Launched in Last 5 Years Continue scaling our large #1 Brand brands in Zydus’ Portfolio1 1st Biosimilar Breast Cancer of TDM-1 (ADC4) Approved Diabetic Dyslipidemia and Hypert
Slide 16: Consumer Wellness: Leadership across Multiple Product Categories
Consumer Wellness: Leadership across Multiple Product Categories Consumer Wellness: Brief Overview Leadership Across Multiple Categories Product Category Brand Name Brand Rank2 ▪ Leadership across categories: Skin care, sugar substitutes and hydration 1 Functional ▪ Distribution: 2,600+ field force,
Slide 17: Consumer Wellness: Entry into Fast Growing Digital VMS Market
Consumer Wellness: Entry into Fast Growing Digital VMS Market Expansion in Complementary Geographies and Digital VMS Market with Acquisition of Comfort Click Combined Global Footprint: Consumer Wellness + Comfort Click Comfort Click’s VMS Portfolio Comfort Click's business portfolio: i. WeightWorld
Slide 18: US Formulations: Scaled Presence across Generics and Specialty Pharma
US Formulations: Scaled Presence with Comprehensive Portfolio across Generics and Specialty Pharma US Formulations: Brief Overview 487/ Multiple #4 225+ #1 Top 3 Dosage $1.3bn 423 Forms1 Rank in the US Gx market in ANDAs Filed / Number of products Rank in ~25% of Covered Rank in ~55% of Covered Tran
Slide 19: US Formulations: Deep 505(b)(2) & Rare Disease Portfolio
US Formulations: Deep 505(b)(2) & Rare Disease Portfolio Expanding Presence in Specialty Space through In-house Development as well as Inorganic Moves In-House Development Acquisitions 9▪ 505(b)(2) Molecules in pipeline Oral Liquids (LiqMeds) 3▪ NDA approvals and launches so far – ZituvioTM (Sitagli
Slide 20: International Markets Formulations: Fast Growing Branded Generics & Generics
International Markets Formulations: Fast Growing Branded Generics & Generics business across Emerging Markets and Europe Strong Growth in International Markets Meaningful Presence in Multiple BGx Markets and Select Gx EU Markets Revenue (INR Mn) 17.9% 21,947 19,294 15,794 38.1% 14,778 10,698 FY23 FY
Slide 21: MedTech: Selectively Grow In Focus Areas
MedTech: Selectively Grow In Focus Areas of Orthopaedics, Cardiology and Nephrology Expand in Focus Areas of Orthopaedics, Cardiology and Nephrology Orthopaedics Cardiology Zydus MedTech – Growth levers Inorganic pipeline Product launches, inorganic opportunities ✓ Entry into global Arthroplasty mar
Slide 22: Amplitude Surgical to Act as a Platform for Global MedTech Strategy
Amplitude Surgical to Act as a Platform to Execute Zydus’ Global MedTech Strategy Value chain positioning Geographic footprint International distributors Research and Development 20 distribution centres across Europe, ▪ Run fully in-house with 30+ active patents LATAM, Africa, Middle East, and APAC
Slide 23: Moving Up in the Innovation Value Curve Led by R&D Investments
Moving Up in the Innovation Value Curve Led by R&D Investments and Centres of Excellence (CoE) Moving Up the Innovation Curve Complex Generics Vaccines NCEs Specialty Portfolio: Generics Biosimilars 505(b)(2) & Rare Diseases Fully Built Our R&D Team… …with Consistent R&D Investment… …And CoEs at the
Slide 24: NCE Pipeline for Global Markets
NCE Pipeline for Global Markets Deep NCE Pipeline at various Stages of Development NCEs Pipeline Innovation Led Products Lead Indication & Drug Pre- Project Target Optimiz IND Phase I Phase II Phase III NDA Launch (Market) Disc. clinical ation First indigenously developed NCE by an Indian Pharmaceut
Slide 25: Saroglitazar: Addressing Unmet Medical Needs in PBC Globally
Saroglitazar: Addressing Unmet Medical Needs in PBC Globally Saroglitazar – Overview of Opportunity PBC Prevalence Primary Biliary Cholangitis (PBC) Commercialization Strategy ~0.1 Mn patients1 • The adjusted 2021 PBC prevalence was 40.9 per 100,000 adults in United States. The total adult populatio
Slide 26: Usnoflast: Novel NLRP3 Inhibitor for Neurodegenerative and Autoimmune Diseases
Usnoflast: Novel NLRP3 Inhibitor Aimed at Addressing Unmet Needs in Neurodegenerative and Autoimmune Diseases Amyotrophic Lateral Sclerosis (ALS) Ulcerative Colitis (UC) ▪ A progressive, fatal neurodegenerative disease which ▪ Affects ~ 5 mn people globally1 affects nerve cells controlling voluntary
Slide 27: Desidustat: Novel Oral Alternative to Injectable ESAs
Desidustat: Novel Oral Alternative to Injectable ESAs Approved in India for Anemia in CKD Patients ~17% Prevalence of CKD patients in INDIA1 150.5 Mn People are estimated to be living with CKD in CHINA1 (~10.6% of population) • Granted an exclusive license to a Chinese company for China, • Phase IV
Slide 28: Biosimilars: Increasing Presence in Emerging & Regulated Markets
Biosimilars: Amongst the Key Companies in India, Increasing Presence in Emerging & Regulated Markets Large Biosimilar Portfolio and Pipeline2 Amongst Key Companies in India1 Biosimilars: 16 approved and 13 launched in India Recent Approvals In India, Zydus is #1 Company in Oncology1 Oncology Nivolum
Slide 29: Vaccines: Comprehensive Portfolio with Platform Diversity
Vaccines: Comprehensive Portfolio with Platform Diversity ✓ WHO PQ5 for 1st 1st 2nd 2nd Typhoid Conjugate Indian company to have Company globally to have Indian company receive Indian company to receive and Rabies indigenously developed an approved pDNA vaccine Market Authorization for Market Author
Slide 30: Building on the Growth Opportunity in Biologics CDMO Market
Building on the Growth Opportunity in Biologics CDMO Market Global Biologics CDMO Presents an Attractive Opportunity with a Large, High Growth Market Zydus is Well Positioned to Tap in this Opportunity Global CDMO Market by Modality1 (USD Bn) CAGR CAGR (2019-24) (2024-30F) Leverage Proposed Acquisit
Slide 31: Wide, Compliant Network of Manufacturing Facilities
Wide, Compliant Network of Manufacturing Facilities Overview of Manufacturing Infrastructure Vertical-wise Bifurcation of Manufacturing Sites Global and de-risked manufacturing footprint with Business Vertical No. of Manufacturing Sites 41 Manufacturing presence in India, France, UK, Brazil and Myan
Slide 32: Financial Overview
zyd® Dedicated To Life Financial Overview
Slide 33: Key Financial Metrics
Key Financial Metrics Total Revenues (INR Mn) EBITDA (INR Mn) and EBITDA Margin % 22.4% 27.5% 30.4% 31.0% 32.3% 16.1% 2,32,415 1,95,474 35.2% 70,585 1,72,374 53,843 10.9% 15.8% 1,26,969 41,043 1,14,445 38,599 35,454 FY23 FY24 FY25 H1 FY25 H1 FY26 FY23 FY24 FY25 H1 FY25 H1 FY26 Reported PAT1 (INR Mn)
Slide 34: Revenue by Business Vertical
Revenue by Business Vertical India Formulations (INR Mn) International Markets Formulations (INR Mn) 9.9% 17.9% 21,947 59,281 53,819 19,294 49,067 15,794 38.1% 14,778 8.2% 31,118 10,698 28,769 FY23 FY24 FY25 H1 FY25 H1 FY26 FY23 FY24 FY25 H1 FY25 H1 FY26 US Formulations (INR Mn) Consumer Wellness (I
Slide 35: Board of Directors
zyd® Dedicated To Life Board of Directors
Slide 36: Experienced Leadership with Execution Capabilities and In-depth Industry Knowledge
Experienced Leadership with Execution Capabilities and In-depth Industry Knowledge Technocrat Promoters with Deep Experience… • Over 2 decades of experience in Pharma industry • Over 4 decades of experience in Pharma industry • Has specialization in chemical and pharmaceutical Pankaj Ramanbhai with
Slide 37: ESG Updates
zyd® Dedicated To Life ESG Updates
Slide 38: ESG Highlights
ESG Highlights ESG Performance ESG Ratings Period FY2022 FY2023 FY2024 Climate Change (GHG Emissions) 58%1 reduction by FY2025 w.r.t baseline against 30% reduction by FY2024 54 62 78 39% of renewable energy in the total energy mix Period FY2023 FY2024 FY2025 55 59 61 Water Management Creation of wat
Slide 39: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-22-62711905 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi C
Zydus Lifesciences — Investor Presentation (November 2025) on 6ix